Little is known about functions of microRNA (miR) passenger strands (miR*) or their roles in tumor development or progression. We screened for miRs and miR* with levels that were altered in metastatic colorectal cancer (CRC) cells and human tumor samples and investigated their targets and effects on cell function and tumor progression in mice.
C olorectal cancer (CRC) is the third most commonly diagnosed cancer in men and the second in women, with more than 1.2 million new cases of cancer and 608,700 deaths estimated to occur yearly in the United States. 1 Various risk groups (low, intermediate, high, and metastatic) that reflect relative survival are categorized using histological grade (Gleason score) and clinical TNM stage (local extent and/or nodal/distant metastases). 2 According to these statistics, when detected at an early stage, most patients with CRC can be categorized into the low-risk group, and 90% of these patients can be cured by surgical resection. 3 Despite significant advances in early detection, CRC is often diagnosed at an advanced stage and thereby carries a poor prognosis. 4 Development of novel prognostic biomarkers and targeted therapies may offer early diagnosis and improved treatment of this cancer.
Metastasis, which is a complex, multistep process, has been identified to be responsible for most deaths from cancer, including CRC. 5 Although metastasis is the overwhelming cause of mortality in patients with solid tumors, our understanding of its molecular and cellular determinants is limited. 6 In recent years, identification and characterization of genes and gene products that drive the metastatic process have been the focus of intense interest. Several transcription factors have been revealed to program many of the cell-biological changes needed to execute the initial steps of the invasion-metastasis cascade. 7 Such gene sets are thus providing numerous candidate mediators of metastasis to be validated through functional and clinical studies. Much less insight, however, has been gained into the regulatory networks that establish such altered gene expression states. 8 MicroRNAs (miRNAs), a class of small cellular RNAs acting as agents of the RNA interference pathway, are attractive candidates as upstream regulators of metastatic progression because miRNAs can posttranscriptionally regulate entire sets of genes. 9 Here, with an array-based miRNA profiling, we found that miR-221* (its function almost unknown) and miR-224 (previously linked to cancer) were down-regulated in metastatic CRC cells. Statistical analyses with human cancer tissues reveal that the expression of miR-221* and miR-224 correlated well with survival but were inversely correlated with cancer progression and recurrence. Moreover, miR-221* and miR-224 were found to inhibit migration of CRC cells in vitro and inhibit tumor metastasis in vivo. Furthermore, we showed that overexpression of miR-221* and miR-224 induced the expression of maspin via direct suppression of MBD2, leading to lowered cancer metastasis. These findings indicate that miR-221* and miR-224 may serve as novel CRC biomarkers and promising candidates for the development of new antimetastasis agents.
Materials and Methods

Microarray Analysis of miRNA Expression
The miRNA microarray experiments were performed using Agilent's miRNA microarray system (V2), which contains 723 human and 76 human viral miRNAs catalogued in the Sanger miRNA database version 10.1 (Agilent Technologies, Foster City, CA). Data were collected and normalized to nonfunctional small RNA internal controls. miRNAs exhibiting a fold change of >2.0 at a false discovery rate of 10% were chosen for further study.
miRNA Mimics and Inhibitors
The mature miR-221* sequence was ACCUGGCAUAC AAUGUAGAUUU. miRIDIAN Hairpin Inhibitor hsa-miR-221* (catalog no. IH301163-02; Dharmacon, Pittsburgh, PA) was used to repress the expression of miR-221* in CRC cells, and miRIDIAN Mimic hsa-miR-221* (catalog no. C-301163-01; Dharmacon) was used to overexpress miR-221* in CRC cells. The mature miR-224 sequence was CAAGUCACUAGUGGUUCCGUU. miRIDIAN Hairpin Inhibitor hsa-miR-224 (catalog no. IH300581-08; Dharmacon) was used to repress the expression of miR-224 in CRC cells, and miRIDIAN Mimic hsa-miR-224 (catalog no. C-300581-7; Dharmacon) was used to overexpress miR-224 in CRC cells. miRIDIAN microRNA Hairpin Inhibitor Negative Control #1 and miRIDIAN microRNA Mimic Negative Control #1 were used as controls.
miRNA Real-Time Polymerase Chain Reaction
Total RNA was extracted from treated colon cancer cells and clinical samples with TRIzol (Invitrogen Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. Next, RNA from each sample was used for miRNA real-time polymerase chain reaction (PCR) with miScript PCR Assay Kit (QIAGEN, Valencia, CA) and specific primers for miR-221* and miR-224, respectively, according to the manufacturer's instructions. miR expression was calculated relative to U44 and U48 ribosomal RNA. The expression of miR-221* and miR-224 in cell lines and tissue samples was determined by real-time PCR.
Chromatin Immunoprecipitation
Using published procedures, 10 immunoprecipitated DNA was quantitated by real-time quantitative PCR. Primer sets were chosen to amplify approximately 100 to 150 base pairs around the indicated region. The enrichments of MBD2 and HDAC1 at the examined regions were quantitated relative to the input amount.
In Situ Hybridization
In situ hybridization was performed on deparaffinized human colorectal tissues as previously described. 11 The sequences of the probes containing the 6 dispersed locked nucleic acid modified bases with digoxigenin conjugated to the 5 0 end were as follows: miR-221*, (5 0 ) ATTCTACATTGTATGCCAGGT; miR-224, (5 0 ) AACGGAACCACTAGTGACTTG.
Methylation Assay
DNAs obtained from surgical samples were treated with bisulfite modification and examined for the methylation status of 19 CpG dinucleotides within the maspin gene promoter region as described previously. 12 The maspin gene promoter was amplified from the bisulfite-modified DNA by 2 rounds of PCR using nested primers specific to the bisulfite-modified sequence of the maspin gene CpG island.
Using published procedures, 12 DNAs extracted from cell lines were treated with the CpGenome DNA Modification Kit (Intergen, Burlington, MA). Primer sequences are listed in Supplementary Materials and Methods.
Statistical Analysis
Analysis was performed using SPSS 16.0 for Windows (SPSS Inc, Chicago, IL). Pearson c 2 test or Fisher exact test was used to compare qualitative variables, and quantitative variables were analyzed using Student t test (one-way analysis of variance for differences among 3 groups) or Pearson correlation test. Kaplan-Meier analysis was used to determine survival. The logrank test was used to compare patients' survival between subgroups, and the Cox regression model was used to perform multivariate analysis. Receiver operating characteristic (ROC) curve analysis was used to determine the predictive value of the parameters. P < .05 was considered statistically significant.
Results
miR-221* and miR-224 Are Down-regulated in Metastatic CRC Cells
Using an array-based miRNA profiling (Supplementary Figure 1 ) and quantitative reversetranscription (RT)-PCR ( Figure 1A) , we identified and validated that miR-221* and miR-224 were markedly down-regulated in highly metastatic SW620 cells versus parental nonmetastatic SW480 cells. To determine whether the underexpression of miR-221* and miR-224 was a universal phenomenon in CRC cells, the expression levels of these candidate miRNAs were then investigated in a series of CRC cell lines. Similarly, the expression levels of miR-221* and miR-224 were found to be lower in metastatic CRC cells (KM12L4a, DLD1, LoVo) than in nonmetastatic ones (KM12C, HCT116, HT29) ( Figure 1B and C). Importantly, the miR-221* and miR-224 expression patterns were also recapitulated in SW620 tumor xenografts. We showed that the expression levels of miR-221* and miR-224 were lower in metastasis loci of the mice than in the primary tumor sites ( Figure 1D ). To determine the clinical relevance of miR-221* and miR-224 in human CRC, we investigated miR-221* and miR-224 expression by real-time PCR in normal colon tissue, primary colorectal tumor, and lymph node metastasis (LNM) specimens. MiR-221* and miR-224 were almost undetectable in LNM but were highly expressed in primary colorectal tumor samples ( Figure 1E and F and Supplementary Figure 2 ). In addition, the expression of miR-221* was found to be down-regulated in tumors compared with normal colon tissues (P ¼ .0117) ( Figure 1E ). However, there was no significant difference in expression of miR-224 between normal colon tissues and tumors ( Figure 1F ). These data further support the finding that miR-221* and miR-224 are specifically downregulated in metastatic CRC cells.
miR-221* and miR-224 Are Correlated With Clinicopathological Features
We then asked whether miR-221* and miR-224 are associated with tumor stages. According to the Union of International Cancer Control staging system, the primary CRC samples were divided into 2 subsets (stages I/II and stages III/IV). Importantly, our analysis showed that the expression levels of miR-221* and miR-224 were closely associated with the clinical stage of CRC (P < .001) ( Supplementary Figure 3 ). Furthermore, we investigated the correlations between miR-221* and miR-224 expression and other clinicopathological features. Neither miR-221* nor miR-224 expression correlated with age, sex, or tumor location. However, low levels of miR-221* or miR-224 expression were correlated with poor differentiation, advanced disease stage, large tumor size, and high rates of LNM in patients ( Supplementary Table 1 ), raising the possibility that these 2 miRNAs may serve as novel prognostic markers for advanced/metastatic CRC.
miR-221* and miR-224 Could Be Used as Prognostic Factors of CRC
To evaluate the potential of miR-221* and miR-224 as prognostic indicators, the Kaplan-Meier survival test was performed. It was shown that low levels of miR-221* or miR-224 expression were inversely associated with overall survival (OS) (P < .001) ( Figure 2A ) and disease-free survival (DFS) (P < .001) ( Figure 2B ). Univariate and multivariate analyses further revealed that disease stage, presence of LNM, miR-221*, miR-224, and the combination of miR-221* and miR-224 were independent risk factors for OS and DFS (Supplementary Table 2 ). Thus, examining the levels of miR-221* and miR-224 individually or in combination could be clinically useful for predicting cancer disease stages.
To determine whether the combination of miR-221* and miR-224 was a more accurate prognostic factor in predicting the outcome of CRC, patients were classified into 4 groups according to their miR-221* and miR-224 densities: group I (n ¼ 35), high miR-221* and miR-224 density; group II (n ¼ 27), high miR-221* but low miR-224 density; group III (n ¼ 24), low miR-221* but high miR-224 density; and group IV (n ¼ 22), low miR-221* and miR-224 density. Differences in both OS (P < .001) and DFS (P < .001) were significant among the 4 groups. The 5-year OS and DFS rates were 94% and 93%, respectively, for group I but 9% and 0%, respectively, for group IV ( Figure 2C ). Moreover, clinicopathological factors showing significance by multivariate survival analysis ( Supplementary Table 2 ) and the combination of miR-221* and miR-224 were adopted, and their predictive values were then studied by ROC analysis. All of the adopted factors predicted death and recurrence precisely (P < .05 for all); however, ROC analysis indicated that the predictive value of the combination of miR-221* and miR-224 was the best for both death and recurrence ( Figure 2D ). Taken together, miR-221* and miR-224 may both be negative regulators for metastasis of CRC, and this study is the first to reveal that passenger strand miRNAs can be a significant player in inhibiting tumor progression.
Up-regulation of miR-221* and miR-224 Reduces Tumor Size and Inhibits Metastasis in Mice
To evaluate the therapeutic potential of miR-221* and miR-224 in vivo, miR-221* inhibitor and miR-224 inhibitor (synthetic RNA duplex, Dharmacon, see Materials and Methods) were transfected into SW480-GFP cells, respectively, while miR-221* mimic and miR-224 mimic were transfected into SW620-GFP cells. The cells were then injected subcutaneously into nude mice. Mice that received the SW480 cells with miR-221* inhibitor or miR-224 inhibitor showed increased tumor sizes and reduced survival times, while mice that received the SW620 cells with miR-221* mimic or miR-224 mimic exhibited decreased tumor sizes and prolonged survival times ( Figure 3A and Supplementary Figure 4A and B). Moreover, we performed orthotopic injections with the CRC cells expressing inhibitors or mimics 13 and observed similar effects of miR-221* and miR-224 on cancer growth and survival; injection of miR-221* or miR-224 mimicbearing cells repressed tumor sizes and extended survival in mice, whereas injection of miR-221* or miR-224 inhibitor increased tumor sizes and decreased survival ( Figure 3B and Supplementary Figure 4C and D). To determine the effect of miR-221* and miR-224 on metastasis, we enumerated the CRC cell number in sera from the mice that received orthotopic injection as well as the number of metastases in their major metastatic organs (lung, spleen, liver, and kidney). Underexpression of miR-221* or miR-224 markedly increased the metastatic CRC cell number in serum of the mice ( Figure 3C ) and the number of metastases in the liver of orthotopic SW480 tumor-bearing mice ( Figure 3D ) as well as in other organs (data not shown). In contrast, overexpression of miR-221* or miR-224 suppressed metastasis in SW620 tumorbearing mice. To account for any manipulation errors in these animal models, we evaluated the effect of miR-221* and miR-224 on late-stage CRC metastasis in a tail vein injection mouse model. As expected, miR-221* inhibitor or miR-224 inhibitor induced a pronounced increase of the number of lung metastases and a sharp decrease of survival time in mice treated with SW480 injection, while miR-221* mimic or miR-224 mimic decreased the number of lung metastases and prolonged the survival time in mice treated with SW620 injection ( Figure 3E and F and Supplementary Figure 4E ). Moreover, we showed that down-regulation of miR-221* and miR-224 could also promote the lymphogenous metastasis (Supplementary Figure 5 ). Taken together, these results strongly indicate that miR-221* and miR-224 may have therapeutic efficacy against established CRC tumors as well as late-stage metastasis.
Up-regulation of miR-221* and miR-224 Inhibits Metastasis In Vitro
To gain the molecular mechanism underlying tumor inhibition, we then sought to determine whether miR-221* and miR-224 could regulate metastasis in vitro. We performed standard Matrigel invasion and Transwell migration assays (Corning Inc, Corning, NY) 14 and found that both miR-221* mimic and miR-224 mimic decreased cell invasion and migration, whereas their inhibitors increased the invasion and migration after 12 hours of treatment ( Figure 4A and B) . These data suggest that miR-221* and miR-224 may inhibit cell invasiveness and motility, which are mechanistic determinants for tumor metastasis. To further determine the mechanism of inhibition of tumor metastasis, we measured the tumor growth rate and cell cycle in these genetically altered SW620 and SW480 cells. We found that cell cycle and growth rate were not significantly changed after treatment with miR-221* and miR-224 inhibitors as well as their mimics ( Figure 4C and D) . These results indicate that miR-221* and miR-224 may primarily exert their antimetastatic activity by limiting cell mobility and reducing cancerous spread, probably with limited effects on the speed of cancer growth.
MBD2 Is a Target of miR-221* and miR-224
To determine the targets of miR-221* and miR-224, we screened a large number of potential target proteins in a database library to identify promising miRNA binding seed sequences within 3 0 untranslated region (UTR). Using bioinformatic analyses (microRNA.org, Targetscan, microRNASeq), we found that MBD2 is a candidate target for both miR-221* and miR-224 ( Figure 5A ). To verify this analysis, MBD2 3 0 UTR, containing miR-221* or miR-224 binding site, were cloned downstream of the luciferase open reading frame. On the other hand, MBD2 3 0 UTR, which contains mutated miR-221* or miR-224 binding site, were also introduced into the luciferase construct. The luciferase constructs were transfected into SW480 and SW620 cells. Next, we cotransfected miR-221* mimic and miR-224 mimic to SW620 cells and cotransfected miR-221* inhibitor and miR-224 inhibitor into SW480 cells. Quantitative RT-PCR analysis confirmed that the cotransfection altered the expression of these miRNAs ( Figure 5B ), which in turn significantly affected luciferase expression ( Figure 5C ). We observed consistent reduction of luciferase expression in cells transfected with miRNA binding site mutant plasmids ( Figure 5C ). Using Western blotting and quantitative RT-PCR analyses, we also found that overexpression of miR-221* or miR-224 significantly decreased MBD2 protein and mRNA expression in SW620 cells, whereas knockdown of miR-221* and miR-224 up-regulated MBD2 protein and mRNA expression in SW480 cells ( Figure 5D and E). To further determine the significance of miR-221* and miR-224 expression, we used several additional CRC cells and confirmed that MBD2 mRNA and protein levels were inversely correlated with miR-221* and miR-224 expression ( Supplementary Figure 6A and B). To gain insight on our experimental data in clinical indications, we further examined the expression of miR-221*, miR-224, and MBD2 in primary tumor and metastasis samples of patients with CRC. We observed that CRC LNM samples exhibited up-regulated MBD2 expression and down-regulated miR-221* and miR-224 expression compared with the primary tumor tissues from the same patients ( Supplementary Figure 7) . To further corroborate these findings, in situ hybridization analysis was performed on CRC LNM samples and primary CRC tissues, followed by immunohistochemistry for MBD2 ( Figure 5F ). LNM samples showed high levels of MBD2 and undetectable levels of miR-221* and miR-224, whereas primary CRC cells showed relatively lower levels of MBD2 and readily detectable miR-221* and miR-224 expression. Collectively, these observations from cell lines and patient lymph node tissues suggest that MBD2 may be an important direct target of miR-221* and miR-224. Moreover, we showed that miR-221* and miR-224 have an additive role in controlling MBD2 transcription, as shown by the expression of MBD2 in primary tumor tissues of patients with CRC, which were divided into subgroups as in Figure 2C (Supplementary Figure 8) . Of note, our study is the first to suggest that MBD2 may be a direct tumor metastasis target.
miR-221* and miR-224 Increased the Expression of Maspin Through MBD2 Downregulation
To convincingly validate our data and further show the antimetastasis mechanism of miR-221* and miR-224 via MBD2, we examined the expression of metastasisrelated proteins. Maspin, a recently characterized metastasis suppressor, was found to be negatively associated with MBD2 ( Figure 6A ), whereas some pro-metastasis proteins were found to be positively correlated with MBD2 (data not shown). Maspin expression levels were Figure 6B ). To evaluate the clinical relevance of maspin expression, we found that CRC LNM samples exhibited down-regulated maspin expression compared with the primary tumor tissues from the same patients ( Supplementary Figure 7) . As predicted, the levels of maspin correlated with miR-221* and miR-224 expression but were inversely correlated with MBD2 expression in patients.
To determine the mechanism by which MBD2 regulates maspin expression, we evaluated the mRNA expression level of maspin. Maspin mRNA expression was shown to be significantly down-regulated by MBD2 overexpression in SW480 cells and elevated by MBD2 inhibition in SW620 cells ( Figure 6C ). Because MBD2 was known as a transcription repressor that causes gene silencing through promoter methylation, 15 we further asked whether the underexpression of maspin was caused by epigenetic modifications. Using a methylation-specific PCR method, we evaluated the promoter status of the maspin gene.
Maspin promoter methylation was found to be induced by MBD2 overexpression in SW480 cells and suppressed by MBD2 inhibition in SW620 cells ( Figure 6D ). Furthermore, a total of 19 CpG sites located between nucleotides À194 and þ105 of the maspin promoter were examined by bisulfite sequencing. Consistent with the differential expression of MBD2, dense cytosine methylation was observed in the CpG islands of the maspin promoter procured from LNM specimens; on the other hand, only sporadic cytosine methylation was identified in the CpG islands of the maspin promoter procured from primary colorectal tumor specimens ( Figure 6E ). To mechanistically characterize the epigenetic patterns, we used a demethylating agent, 5-aza-2 0 -deoxycytidine (DAC), and a histone deacetylase inhibitor, trichostatin A (TSA), alone or together and evaluated methylation. We found that demethylation of the maspin gene promoter restored maspin mRNA expression by all of these treatments ( Figure 6C and D) , indicating that the maspin gene might be regulated by both MBD2 and HDACs. However, we cannot exclude the possibility that MBD2 might indirectly bind to an unmethylated maspin gene promoter through HDAC1.
MBD2 Down-regulates Maspin in Association With HDAC1
To further understand the epigenetic mechanism, we performed chromatin immunoprecipitation assays in SW620 cells and confirmed that HDAC1 and MBD2 could bind to the maspin gene ( Figure 7A ). We then applied methylation and acetylation inhibitor as indicated to SW620 cells and found that both MBD2-maspin and HDAC1-maspin interactions could be disrupted by MBD2 inhibition, indicating that MBD2 may be a bona fide target for miR-221* and miR-224 involved in these interactions ( Figure 7B ). However, DAC could only disrupt the MBD2-maspin interaction and had no effect on HDAC1-maspin interaction, indicating that the MBD2maspin interaction required the hypermethylated status of the maspin gene, whereas the HDAC1-maspin interaction did not. Moreover, MBD2 and HDAC1 have been (B) Levels of MBD2 and maspin were assessed by Western blot in SW620 and SW480 cells after MBD2 down-regulation or overexpression. b-actin was used for loading control. (C) miR-221*, miR-224, and MBD2 were overexpressed or down-regulated in SW620 and SW480 cells. Moreover, SW620 and SW480 cells were treated with DAC (5 mmol/L) for 48 hours, TSA (0.5 mmol/L) for 24 hours, or both (DAC for 24 hours, followed by TSA for an additional 24 hours). Levels of maspin mRNA were assessed in treated SW620 and SW480 cells by quantitative RT-PCR. (D) SW620 and SW480 cells were treated as in C. Genomic DNA extracted from the cells was treated with bisulfite and then subjected to methylation-specific PCR using the methylated DNA-specific (M) and unmethylated DNA-specific (U) primer sets. (E) PCR products were sequenced for the 19 CpG sites located between nucleotides À194 and þ105 of the maspin promoter. The horizontal dots represent CpG islands, and the vertical dots represent the individual 5 clones sequenced. Each black dot represents a methylated cytosine residue within the CpG islands. All data are representative of 3 experiments in triplicate. *P < .05, **P < .01.
reported to be able to interact with each other. 15 To further strengthen the significance of epigenetic regulation and elaborate the concrete mechanism, we confirmed this interaction in CRC cells ( Figure 7C ). Collectively, our data indicate that MBD2 regulates the metastasis pathway in association with HDAC1 by epigenetically inhibiting maspin via direct binding.
In summary, our studies have revealed novel metastasis negative regulators miR-221* and miR-224 in CRC by a combination of analyses in patient samples, cell lines, and mouse models. MiR-224 has been shown to affect CRC methotrexate resistance in vitro, 16 consistent with our findings for repressing tumor growth. Previous reports have generally shown that miRNA star forms have functions similar to those of their counterpart miR strands, 17 while we found that miR221* has a novel function in relation to its counterpart miR-221. Mechanistically, we identified that a passenger strand may modify the metastatic repressor maspin through molecular interactions and epigenetic regulations of MBD2 ( Supplementary  Figure 9 ). This information may benefit the development of novel therapeutic targets or diagnostic markers for CRC.
Discussion
In this study, we found that the expression levels of miR-221* and miR-224 negatively correlated with the metastatic abilities of CRC cells both in vitro and in vivo. Statistical analyses further revealed that miR-221* and miR-224 could serve as promising prognostic factors for both severity and recurrence of CRC. Our study showed that miR-221* and miR-224 could synergistically target the same protein MBD2 in CRC cells. Thus, we hypothesized that their combination, which had a greater inhibitory effect on their target, might be a more accurate prognostic factor. Hence, our studies are consistent with the current notion that multiple miRNAs can share a target to synergistically repress one gene. Statistical analyses with a number of clinical CRC samples further confirmed that the predictive value of the combination of miR-221* and miR-224 was the best, suggesting that this combination could be used as a prognostic biomarker of CRC.
MiR-224 is aberrantly expressed in several human neoplasms [18] [19] [20] and is characterized by contradictory properties, because it can promote 18 or inhibit 19 cancer cell growth, depending on the type of malignancy. Accumulating evidence has shown that miR-224 is up-regulated in CRC compared with normal colorectal tissue. 21, 22 However, the relative expression levels of miR-224 between a primary colorectal tumor and its LNM tissue or among different stages of CRC are still unclear.
Here, we found that miR-224 expression levels decreased as CRC progressed from an early-stage tumor to a latestage tumor and LNM, which finally leads to metastasis and death. On the other hand, the role of miRNA* in tumor metastasis is totally undefined. Although several studies have reported that the function of miRNA* in cancer cells may be similar to their counterpart strand, 17, 23 we showed here that miR-221* possessed a metastasis-suppressive ability distinct from its counterpart miR-221 [24] [25] [26] [27] (Supplementary Figure 10 ).
In the present study, expression levels of miR-221* and miR-224 were shown to significantly modulate tumor size, the number of metastatic cells, and survival time in nude mouse models. However, in vitro experiments revealed that miR-221* and miR-224 only modulated invasion and migration and had no impact on cell viability and cell cycle progression of CRC cells. This inconsistency might have resulted from the antiangiogenic effect of maspin, which was shown to be a downstream target of miR-221* and miR-224. 28 The effect of maspin has mostly been studied in endothelial cells. In vitro, maspin acts directly on cultured endothelial cells to impede their migration toward basic fibroblast growth factor and vascular endothelial growth factor and to limit mitogenesis and tube formation; in vivo, it blocks neovascularization. 28 Our results showed that maspin did not affect mitogenesis of CRC cells in vitro. However, maspin could be synthesized in CRC cells and function on endothelial cells in vivo because it is a secreted protein. 29 To our knowledge, the present study revealed for the first time a novel role of miR-221* and miR-224 in CRC metastasis. A new antimetastatic mechanism mediated by these miRNAs was further identified as epigenetic regulation of metastatic promoter and inhibitor by targeting MBD2. Our studies identified that miR-221* and miR-224 may be potential prognostic predictors and therapeutic targets for CRC.
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Supplementary Materials and Methods
In Vitro Motility and Proliferation
Cell migration assays were performed in 24-well Transwell chambers (Corning, Corning, NY). Cells in serum-free medium (2.5 Â 10 4 cells per well) were added to the upper chamber. After 24 hours, the number of cells that migrated through the membrane to the lower chamber was counted. For invasion assays, Matrigel (1:3; BD) was added to the Transwell membrane chambers and incubated for 4 hours, and cells were seeded. Cells, which had migrated to the lower chamber, were counted after 72 hours. For blocking experiments, cells were added to the upper chambers in the presence of LM609 (10 mg/mL) or control mouse immunoglobulin G (10 mg/mL); in addition, filter undersides were precoated with fibrinogen (20 mg/mL) in phosphate-buffered saline (PBS) and blocked with 2.5% bovine serum albumin in 0.2% Tween 20/PBS in migration assay. Migration and invasion assays were performed in triplicate for each cell line tested. For evaluation of cell growth in soft agar, cells (3000 cells/well) were resuspended in Dulbecco's modified Eagle medium containing 10% fetal bovine serum with 0.35% agarose and layered on top of 0.5% agarose in Dulbecco's modified Eagle medium on 6-well plates. Cultures were maintained for 14 days, and plates were stained with 0.3 mL of 0.005% Crystal Violet for more than 1 hour. Colonies (larger than 200 mm) were then counted using a dissecting microscope. Each experiment was performed in triplicate.
Luciferase Assays
The 3 0 UTR of the human MBD2 gene was PCR amplified using the following primers: MBD2 forward (Fw), 5 0 -TCTAGAGTACCCGAGCACATAGAG-3 0 ; MBD2 reverse (Rw), 5 0 -TCTAGACAGAGGAAGGCTAACGAG-3 0 . The gene was then cloned to the downstream of the Renilla luciferase stop codon in pGL3 control vector (Promega, Madison, WI), giving rise to the p3 0 UTR-MBD2 plasmid. This construct was used to generate, by inverse PCR, the p3 0 UTR mir-221* mut-MBD2 plasmids (primers: Fw, 5 0 -GAAGCTGAGCTTTTGGGCGGGCCTGCCAGGTGCAAT CT-3; Rw, 5 0 -CTTCGACTCGAAAACCCGCCCGGACGGT CCACGTTAGA -3 0 ) and p3 0 UTR mir-224 mut-MBD2 plasmid (primers: Fw, 5 0 -CAGTTAAAGATTATTCGCGGGG CACTGTATATAAACA-3 0 ; Rw, 5 0 -GTCAATTTCTAATAAGC GCCCCGTGACATATATTTGT-3 0 ). SW480 and SW620 cells were cotransfected with 1 mg of p3 0 UTR-MBD2 and with p3 0 UTR mir-221* mut-MBD2 or p3 0 mir-224 UTR-MBD2 plasmids and 1 mg of a Renilla luciferase expression construct, pRL-TK (Promega), using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Cells were harvested 24 hours posttransfection and assayed with Dual Luciferase Assay (Promega) according to the manufacturer's instructions. Three independent experiments were performed in triplicate.
Western Blot and Immunoprecipitation
Goat polyclonal antibodies against MBD2 and HDAC1 and rabbit polyclonal antibody against uPA were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit monoclonal antibody against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was from Cell Signaling Technology (Boston, MA). Goat and rabbit immunoglobulin G were obtained from Jackson Immu-noResearch (West Grove, PA).
Immunohistochemical Analysis
Tissues were formalin fixed and paraffin embedded, and sections were consecutively cut (3-to 4-mm thickness) for immunohistochemistry analysis using a Dako EnVision System (Dako Cytomation GmbH, Hamburg, Germany) according to the manufacturer's instructions. Briefly, the paraffin sections were dewaxed, rehydrated, and incubated in 3% H 2 O 2 for 10 minutes in the dark at room temperature to quench the endogenous peroxidase activity. Antigen retrieval was performed in citrate buffer (pH 6.0) using the autoclave sterilizer method. Subsequently, the sections were blocked with normal rabbit or goat serum diluted in PBS (pH 7.4) for 20 minutes at 37 C, followed by incubation at 4 C overnight with the primary antibody goat anti-MBD2 (diluted 1:150; Santa Cruz Biotechnology). After rinsing in fresh PBS for 15 minutes, slides were incubated with horseradish peroxidase-linked rabbit anti-goat antibody at 37 C for 40 minutes, followed by reaction with 3,3 0 -diaminobenzidine substrate solution (Dako Cytomation, Carpinteria, CA). The immunohistochemical staining was assessed and scored by calculating the percentage of positive CRC cells and the immunostaining intensity as described previously.
Target Analysis
Bioinformatic analysis was performed using microRNA.org (http://www.microrna.org), Targetscan (http://www.targetscan.org/), and microRNASeq (https:// cm.jefferson.edu/).
